Raxibacumab
Mechanism :
Raxibacumab is a recombinant human IgG1 lambda monoclonal antibody which binds and neutralizes free protective antigen (PA) component of Bacillus anthracis toxin.
Indication :
- Treatment of inhalational anthrax following exposure to Bacillus anthracis in combination with appropriate antimicrobial therapy
Contraindications :
No contraindications.
Dosing :
IV:
≤15 kg:
80 mg/kg as a single dose.
>15 kg to 50 kg:
60 mg/kg as a single dose.
>50 kg:
40 mg/kg as a single dose.
Note: Administer
diphenhydramine ≤1 hour prior to administration of raxibacumab to reduce the risk of infusion reactions.
Adverse Effect :
Skin rash, pain, pruritus.
Interaction :
Belimumab: Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab.
Hepatic Dose :
No dosage adjustments are recommended; effects not studied.